Theralase reports 21% revenue drop but shows promising cancer drug trial results with 65% patient response rate

Theralase Technologies reported a 21% revenue decline to CAD 816,468 for 2025 but reduced its net loss slightly to CAD 4.12 million. The company highlighted positive interim results from its Phase II clinical trial for Ruvidar®, a cancer drug targeting BCG-unresponsive bladder cancer, with 65.2% of patients achieving complete response. The trial is ongoing, and Theralase plans regulatory submissions in 3Q2026, aiming for approvals by mid-2027. They also announced a new collaboration with Ferring Pharmaceuticals to expand the trial and are pursuing commercialization and partnerships globally.